CN102070541A - Letrozole I-type crystal and preparation method thereof - Google Patents
Letrozole I-type crystal and preparation method thereof Download PDFInfo
- Publication number
- CN102070541A CN102070541A CN2010105210690A CN201010521069A CN102070541A CN 102070541 A CN102070541 A CN 102070541A CN 2010105210690 A CN2010105210690 A CN 2010105210690A CN 201010521069 A CN201010521069 A CN 201010521069A CN 102070541 A CN102070541 A CN 102070541A
- Authority
- CN
- China
- Prior art keywords
- letrozole
- crystallization
- anhydrous
- type
- crystal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
Abstract
The invention relates to a letrozole I-type crystal and a preparation method thereof, in particular to an anhydrous letrozole crystal. The structure and characteristics of the anhydrous letrozole crystal are represented by X-radial powder diffraction, differential scanning calorimetry, infrared spectrum and the like. Characteristic diffraction peaks, which are positioned at the degrees 2theta of 13.08+/-0.2, 14.06+/-0.2, 17.04+/-0.2, 21.44+/-0.2 and 29.24+/-0.2, are positioned in the X-radial powder diffraction pattern of the crystal powder. The anhydrous letrozole crystal is simple in preparation process, the yield and purity of the crystal are high, and the anhydrous letrozole crystal has good stability and is suitable for production of medicinal preparations. The invention also provides a method for preparing the anhydrous letrozole crystal by using an anhydrous and pure organic solvent as a crystallization solvent and application of the crystal in the medicinal preparations which are used for treating advanced breast cancer of a patient after menopause by antiestrogen.
Description
Technical field
The present invention relates to letrozole I type crystallization and preparation method thereof, and contain letrozole I type crystalline pharmaceutical composition.
Background technology
Letrozole, English name Letrozole, two (4-cyano-phenyl) methyl of chemical name 1-[]-1,2, the 4-triazole is an arimedex of new generation, is artificial synthetic benzyl triazole derivative.Letrozole makes decrease in estrogen by suppressing aromatizing enzyme, thereby eliminates the hormesis of oestrogenic hormon to tumor growth.The result of study of inside and outside shows that letrozole can effectively suppress male sex hormone and transform to oestrogenic hormon, and postmenopausal women's oestrogenic hormon is mainly derived from the aromatize of androgen precurosor material in peripheral tissues, so it is specially adapted to treat postclimacteric patient with breast cancer.
Patent and document (seeing the following form) etc. all have narration to its preparation.Yet the physical and chemical parameter of the letrozole of different bibliographical informations exists than big-difference, for example:
There is very big difference in the fusing point of above bibliographical information compound letrozole compound, and the difference of the letrozole physico-chemical property of reporting for different document is not seen systematic study and/or explanation at present.The inventor finds that first there is complicated polymorphism in letrozole, and mostly is the mixture that duplicates crystalline polymorph body and/or unformed powder greatly by the letrozole crystallization of the conventional preparation of document, and therefore measured fusing point and melting range are all variant.
The known drug crystal formation can have influence on the biologic activity of solubleness, bio-absorbable and the medicine of medicine.Therefore, the medicine crystal formation is to pharmaceutical activity, particularly to the pharmaceutical activity of oral solid formulation, comprises therapeutic activity, untoward reaction of medicine etc., can have remarkably influenced.In addition, the medicine crystal formation also may have influence on the preparation process of medicine, shelf-life etc. and the closely-related aspect of medicinal application.
In general, in medicinal application, when especially being applied to medicine with the solid preparation form, active substance should have definite physical aspect and clear and definite physico-chemical property.The physical aspect and/or the physico-chemical property of active substance are inconsistent, can cause the difficulty of the preparations shaping technical elements of solid preparation and even liquid preparation, and can cause the preparation end product to be difficult to be applied to clinical owing to character is inhomogeneous.This shows that can stablize provides the letrozole with definite physico-chemical property,, have important use and be worth and theory significance for preparation its preparation, especially solid preparation.
Summary of the invention
One object of the present invention is to provide a kind of new crystal of letrozole, its crystalline feature characterizes by fusing point, X-ray powder diffraction (XRD), differential scanning calorimetric analysis (DSC), infrared spectra (IR), and this crystal formation possesses the needed performance of preparation solid pharmaceutical preparation.
Another object of the present invention is to provide the preparation method of letrozole new crystal.
A further object of the present invention is to provide the application of letrozole new crystal in pharmaceutical preparation, contains the pharmaceutical composition of this letrozole new crystal specifically.
The inventor is in preparation letrozole crystalline process, find to use anhydrous organic solvent, as the neat solvent of anhydrous isopropyl alcohol, anhydrous chloroform, anhydrous propanone or its mixture as recrystallisation solvent, method by recrystallization is carried out crystallization to the letrozole crude product, can obtain letrozole new crystal of the present invention.Detect and analyze by this crystallization being carried out fusing point measurement, X-ray powder diffraction, DSC, IR collection of illustrative plates etc., the crystallization that conclusive evidence obtains is a kind of novel letrozole crystallization, is called the crystallization of letrozole I type.
Letrozole I type of the present invention crystallization can characterize by its X-ray powder diffraction.When carrying out the X-ray powder diffraction with the Cu source of radiation, described crystallization be positioned at 2 θ be 13.08 ± 0.2,14.06 ± 0.2,17.04 ± 0.2,21.44 ± 0.2,
Characteristic diffraction peak, the relative intensity (I/I at these peaks
0) all more than or equal to 35%.Further, described crystallization in the X-ray powder diffraction, can also further comprise be positioned at 2 θ be 16.14 ± 0.2,19.64 ± 0.2,22.10 ± 0.2,23.30 ± 0.2,25.66 ± 0.2,26.02 ± 0.2,266.96 ± 0.2,29.64 ± 0.2,30.96 ± 0.2,40.20 ± 0.2,
Characteristic diffraction peak, the relative intensity at these peaks is all more than or equal to 15% (see figure 1).
The present invention also adopts differential scanning calorimetric (DSC) technology, and crystallization characterizes (see figure 2) to letrozole I type, wherein has differential scanning calorimetric heat absorption maximum value at 186.3 ℃, and this endothermic process shows as a sharp-pointed endotherm(ic)peak on the DSC spectrogram; For the sample of thorough drying, this endotherm(ic)peak is unique significant endotherm(ic)peak on the DSC spectrogram, does not have obvious exothermic peak on the spectrogram.
Can confirm that by XRD spectra the present invention has obtained crystalline product, can confirm that in conjunction with the DSC spectrogram crystallization of letrozole I type has single crystal form.
Letrozole I type crystalline melting range of the present invention is: 183.6～187.8 ℃.
Letrozole I type crystalline infared spectrum of the present invention as shown in Figure 3, wherein 2232,1608,1504,1435,1409,1271,1200,1139,1004,955,868,858,791,678,658,569,555,548 and 494cm
-1Strong absorption peak is arranged.
Letrozole I type of the present invention crystallization is an anhydrous crystal, and water absorbability is low, and after 25 ℃ and relative humidity were placed 10 days 92.5% time, Karl Fischer method recorded water content and is no more than 0.1%.Letrozole I type anhydrous crystal bulk drug is enclosed within the aluminium foil bag, placed 6 months for 75% time in 40 ℃ of temperature and relative humidity, its outward appearance, fusing point, water content and content have no significant change.Letrozole I type anhydrous crystal bulk drug is enclosed within the aluminium foil bag, placed 12 months under 25 ℃ of temperature and relative humidity 60% condition, its outward appearance, fusing point, water content and content have no significant change.
According to a further aspect in the invention, provide preparation letrozole I type crystalline preparation method.Studies show that, the water-containing crystal solvent can influence the purity of letrozole crystallized product to some extent, and the mixture that crystalline polymorph body and/or unformed powder occur, the present invention adopts anhydrous pure organic solvent to prepare the crystallization of letrozole I type as the method for recrystallisation solvent by recrystallization.Particularly, the letrozole dissolving crude product in anhydrous organic solvent, is filtered, filtrate decompression concentrates, and drying promptly gets the crystallization of letrozole I type.Described anhydrous organic solvent can be the neat solvent of anhydrous isopropyl alcohol, anhydrous chloroform, anhydrous propanone or their mixing solutions.
Because the crystallization of letrozole I type has stable crystal habit and clear and definite physicochemical property, make it be suitable for making tablet or other solid preparations even liquid preparation, the range of application of letrozole I type crystallization in field of pharmaceutical preparations is consistent with letrozole compound of the prior art, makes the desired using value that has of letrozole obtain necessary assurance.Therefore, the present invention provides the application of letrozole I type crystallization in pharmaceutical preparation simultaneously, contain letrozole I type crystalline pharmaceutical composition specifically, this pharmaceutical composition contains the letrozole I type crystallization of significant quantity and optional pharmaceutically acceptable carrier and/or excipient, can be used for the treatment of patient after the advanced breast cancer menopause of estrogen antagonist treatment.Described " treatment significant quantity " is meant under this dosage, and the letrozole I type anhydrous crystal of the present invention symptom of can improving or palliate a disease maybe can suppress or block advancing of disease.
Aforementioned pharmaceutical compositions can further be mixed with the form that can supply with medicine according to the conventional formulation method, comprises per os or parenteral admin form, for example comprises tablet, capsule, pulvis, granule, lozenge, suppository, patch, gelifying agent.Preferred dosage form is tablet and capsule.These compositions that can supply with medicine can also be prepared into sustained-release preparation or targeting preparation as required.
The formulation of oral administration can be tablet and capsule, and they can contain conventional excipients such as tackiness agent, comprise syrup, dextrin, starch slurry, gum arabic, gelatin, sorbyl alcohol, tragacanth, Vltra tears or polyvinylpyrrolidone etc.; Weighting agent is as lactose, sucrose, W-Gum, calcium phosphate, sorbyl alcohol, N.F,USP MANNITOL, Microcrystalline Cellulose, calcium sulfate or glycine; The compressing tablet lubricant is as Magnesium Stearate; Disintegrating agent such as croscarmellose sodium, starch, polyvinylpyrrolidone, Crospovidone, hydroxyethylamyle sodium, low-substituted hydroxypropyl cellulose sodium or Microcrystalline Cellulose and/or pharmaceutically acceptable wetting agent are as sodium lauryl sulphate, water, ethanol etc.In addition, also available any pharmaceutically acceptable tinting material colouring is with the outward appearance of improving them and/or be convenient to the patient and recognize product and unit dosage level.
Rule of thumb and consider that the standard method and the reference of this area, those skilled in the art can select above-mentioned various carrier and/or vehicle at an easy rate and determine its consumption.
The fusing point that the letrozole I type crystallization that the present invention prepares has stable morphology and determines, chemical stability is good, the letrozole of this form has possessed the needed performance of preparation solid preparation, good, the easy-formation of compressibility when preparation, make that raw materials cost reduces greatly when industrial preparation medicine, and it is convenient to store, and production operation is more easy, and quality is more easy to control.
The letrozole I type anhydrous crystal bulk drug that makes can adopt preparation technique commonly used to prepare the letrozole particle, and then is used to prepare solid preparation, as tablet and capsule.After letrozole I type anhydrous crystal sieved, mix with thinner (as lactose, pregelatinized Starch or starch) and disintegrating agent auxiliary materials such as (as W-Gum, low-substituted hydroxypropyl cellulose or polyvinylpolypyrrolidone), add tackiness agent (as Microcrystalline Cellulose, gum tragacanth or gelatin or HPMC) system softwood, the wet grain of the system of refiltering, dry, sieve whole grain, get final product the anhydrous letrozole bulk drug of I crystal formation particle.Above-mentioned particle and lubricant (as Magnesium Stearate) are mixed, can suppress the letrozole tablet; With the above-mentioned particle capsulae vacuus of packing into, can prepare the letrozole capsule.
The solid preparation that uses the anhydrous water preparation of letrozole I type is in pH is 4.5 dissolution medium, and the dissolution rate after 30 minutes is greater than 85%.With the letrozole solid preparation after 25 ℃ and relative humidity are placed 10 days 92.5% time, its outward appearance, related substance, dissolution rate and content have no significant change, the letrozole solid preparation is enclosed within the aluminium foil bag, placed 6 months for 75% time in 40 ℃ of temperature and relative humidity, its outward appearance, dissolution rate and content have no significant change.The letrozole solid preparation is enclosed within the aluminium foil bag, placed 12 months under 25 ℃ of temperature and relative humidity 60% condition, its outward appearance, related substance, dissolution rate and content have no significant change.
The invention has the beneficial effects as follows: the crystallization of a kind of novel letrozole I type, this crystalline purity height, good stability is particularly suitable for preparation production; And prepare this crystalline technological process in simple and practical, the solvent for use amount is few, and crystallization is complete rapidly, the yield height.
Description of drawings
Fig. 1 is the powder x-ray diffraction spectrogram of letrozole I type anhydrous crystal.
Fig. 2 is differential scanning calorimetric analysis (DSC) spectrogram of letrozole I type anhydrous crystal.
Fig. 3 is the infrared spectrogram of letrozole I type anhydrous crystal.
Fig. 4 is the powder x-ray diffraction spectrogram of existing letrozole crystal formation.
Fig. 5 is the DSC spectrogram of existing letrozole crystal formation.
Embodiment
The present invention is further illustrated below in conjunction with drawings and Examples.But embodiment does not constitute any restriction to the present invention.
Detecting instrument and condition:
1, X-ray powder diffraction
Instrument: RIGAKU x-ray diffractometer (D/Max-IIIA, Cu target)
Condition: divergency (1 °), accept slit (0.3mm), the colourity (1 °) of loosing, pipe is pressed 40kV, pipe stream 60mA.
2, dsc
Instrument: NETZSCH DSC204 type differential scanning calorimeter
Condition: 25～210 ℃ of temperature ranges, 10.00 ℃/min of heating rate
3, infrared spectra
Instrument: Nicolet Magna 550 type infrared spectrometers
Condition: pressing potassium bromide troche.
Two (4-cyano-phenyl) methyl of [embodiment 1] 1-[]-1,2, the preparation of 4-triazole (letrozole) contrast crystal formation
Two (4-cyano-phenyl) methyl of 1-[of contrast crystal formation]-1,2,4-3-triazole compounds crude product can adopt U.S. Pat 20,070, the method preparation of describing in 100,149: letrozole crude product 20g is added the 140ml methylene dichloride, add 500ml methyl alcohol then.Stir 10min, remove partial solvent,, add 350ml water, stir 1h until remaining 105～120ml mixed solvent at temperature rotary evaporation below 40 ℃.Form a large amount of white solids and filter, with the 140ml washing,, obtain the 15.2g white crystalline powder, yield 76% simultaneously at 55～60 ℃ of following decompress filter 4h.Its XRD spectra, DSC spectrogram are seen Fig. 4, Fig. 5 with reference to U.S. Pat 20,070,100,149.
Two (4-cyano-phenyl) methyl of [embodiment 2] 1-[]-1,2, the preparation of 4-triazole (letrozole) I type crystalline
Solvent acetone adds Anhydrous potassium carbonate, shakes up, and the 4ALinde molecular sieve is put in the distillation in 4 hours that refluxes simultaneously in the receiving flask, gets the anhydrous propanone solvent.With 50g letrozole crude product, add in about 1.5L anhydrous propanone solvent, the dissolving after-filtration, filtrate decompression concentrates (0.1Mpa, 50 ℃), and concentrate drying gets the 43g white crystalline solid, yield 86% to constant weight (0.1Mpa, room temperature).
Its XRD spectra as shown in Figure 1, the DSC spectrogram as shown in Figure 2, infrared spectra is as shown in Figure 3.Wherein the main diffraction peak of XRD spectra sees Table 1.
Table 1
| The peak | 2θ | The d value | I/I 0 | The peak | 2θ | The d value | I/ |
| 1 | 13.08 | 6.76 | 40 | 10 | 25.66 | 3.47 | 23 |
| 2 | 14.06 | 6.29 | 82 | 11 | 26.02 | 3.42 | 19 |
| 3 | 16.14 | 5.49 | 15 | 12 | 26.96 | 3.30 | 29 |
| 4 | 17.04 | 5.20 | 100 | 13 | 29.24 | 3.05 | 36 |
| 5 | 19.64 | 4.52 | 24 | 14 | 29.64 | 3.01 | 22 |
| 6 | 21.44 | 4.14 | 35 | 15 | 30.96 | 2.89 | 29 |
| 7 | 22.10 | 4.02 | 26 | 16 | 35.68 | 2.51 | 7 |
| 8 | 23.30 | 3.81 | 23 | 17 | 40.20 | 2.24 | 18 |
| 9 | 23.94 | 3.71 | 7 | 18 | 47.30 | 1.92 | 15 |
Two (4-cyano-phenyl) methyl of [embodiment 3] 1-[]-1,2, the preparation of 4-triazole (letrozole) I type crystalline
The solvent Virahol added calcium oxide (200g/L) backflow after 3 hours, distilled then, and distillate adds hydrolith and further distills, and gets the anhydrous isopropyl alcohol solvent.With 50g letrozole crude product, add in about 1.5L anhydrous isopropyl alcohol solvent, the dissolving after-filtration, filtrate decompression concentrates (0.1Mpa, 50 ℃), and concentrate drying gets the 40g white crystalline solid, yield 80% to constant weight (0.1Mpa, room temperature).
Two (4-cyano-phenyl) methyl of [embodiment 4] 1-[]-1,2, the preparation of 4-triazole (letrozole) I type crystalline
Solvent chloroform adds Anhydrous potassium carbonate after dry 24 hours, adds anhydrous Vanadium Pentoxide in FLAKES again and refluxes, distillation.Get the anhydrous chloroform solvent.With 50g letrozole crude product, add in about 1.5L anhydrous chloroform solvent, the dissolving after-filtration, filtrate decompression concentrates (0.1Mpa, 50 ℃), and concentrate drying gets the 42g white crystalline solid, yield 84% to constant weight (0.1Mpa, room temperature).
Two (4-cyano-phenyl) methyl of [embodiment 5] 1-[]-1,2, the preparation of 4-triazole (letrozole) I type crystalline
With 50g letrozole crude product, add in about 1.0L anhydrous chloroform and the 0.5L anhydrous isopropyl alcohol mixed solvent, the dissolving after-filtration, filtrate decompression concentrates (0.1Mpa, 50 ℃), and concentrate drying gets the 41g white crystalline solid, yield 82% to constant weight (0.1Mpa, room temperature).
Letrozole I type of the present invention crystallization sees the following form 2 with the physicochemical property contrast of contrast crystal formation:
Table 2
| Numbering | Fusing point (℃) | The main diffraction peak similarities and differences of XRD |
| The I crystal formation | 183.6～187.8 | 47.3 ° located absorption, the contrast crystal formation does not have |
| The |
180～183 | 25.6 ° located absorption, the I crystal formation does not have |
The preparation of [embodiment 6] solid pharmaceutical preparation
Prescription 1:
Method for making: mentioned component according to the conventional formulation method mix, direct compression.
Prescription 2:
Method for making: letrozole I type crystallization and starch, lactose, dextrin mix by the equivalent multiplication method, add the HPMC solution prepare in advance and make softwood, and 20 mesh sieves are granulated, 60 ℃ of dryings 30 minutes, and the whole grain of 18 mesh sieves adds micropowder silica gel, mixes, and packs 2 into
#Capsule gets final product.
Prescription 3:
Method for making: mentioned component according to the conventional formulation method mix, direct compression.
[embodiment 7] influence factor controlled trial
Table 3
| Investigate | Prescription | 1 | |
Prescription 3 |
| Dissolution rate | Good | Good | Difference |
| Compressibility | Good | / | Better |
| Disintegration | Good | Better | Difference |
The purpose of development crystal formation mainly is the problem that solves dissolution rate, increases stripping.According to 2010 editions pharmacopeia dissolution rate test card where there is light sides 1～2 its at 15 minutes dissolution rates all more than 80%.3 have only below 70% and write out a prescription at 15 minutes dissolution rates.Under the prerequisite of auxiliary material unanimity, every investigation index of prescription 1 is better than writing out a prescription 3, therefore the I crystal formation is not only variant at aspects such as fusing point, solubleness, dissolution of crystals degree with the product of contrast crystal formation, and every investigation indexs such as the latter's stability, preparation dissolution rate, compressibility, disintegration all are not so good as letrozole I crystal formation of the present invention.
More than the description of better embodiment of the present invention is not limited the present invention, those skilled in the art can make various changes or distortion according to the present invention, only otherwise break away from spirit of the present invention, all should belong to the scope of claims of the present invention.
Claims (9)
1. letrozole I type crystallization is characterized in that described crystallization in Cu X-ray powder diffraction, is that 13.08 ± 0.2,14.06 ± 0.2,17.04 ± 0.2,21.44 ± 0.2,29.24 ± 0.2 degree places have characteristic peak at 2 θ.
2. letrozole I type as claimed in claim 1 crystallization is characterized in that described crystallization is that 16.14 ± 0.2,19.64 ± 0.2,22.10 ± 0.2,23.30 ± 0.2,25.66 ± 0.2,26.02 ± 0.2,266.96 ± 0.2,29.64 ± 0.2,30.96 ± 0.2,40.20 ± 0.2,47.30 ± 0.2 degree places have characteristic peak at 2 θ further.
3. letrozole I type as claimed in claim 1 crystallization is characterized in that described crystallization by differential scanning calorimetric analysis, has an endotherm(ic)peak, and peak value is positioned at 186.3 ℃.
4. letrozole I type as claimed in claim 1 crystallization is characterized in that described crystallization has infrared spectrogram as shown in Figure 3.
5. the described letrozole I of preparation claim 1 type crystalline method is characterized in that with anhydrous organic solvent letrozole being carried out crystallization.
6. method as claimed in claim 5 is characterized in that comprising step: the letrozole dissolving crude product in anhydrous organic solvent, is filtered, and filtrate decompression concentrates, and drying promptly gets the crystallization of letrozole I type.
7. method as claimed in claim 6 is characterized in that described anhydrous organic solvent is anhydrous isopropyl acetone, anhydrous chloroform, anhydrous propanone or their arbitrary combination.
8. method as claimed in claim 6 is characterized in that described filtrate is at 0.1Mpa, 50 ℃ of following concentrating under reduced pressure, and drying is at 0.1Mpa, carries out under the room temperature.
9. contain the described letrozole I of claim 1 type crystalline pharmaceutical composition.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010105210690A CN102070541B (en) | 2010-10-25 | 2010-10-25 | Letrozole I-type crystal and preparation method thereof |
| PCT/CN2011/001760 WO2012055163A1 (en) | 2010-10-25 | 2011-10-24 | Letrozole type i crystal and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010105210690A CN102070541B (en) | 2010-10-25 | 2010-10-25 | Letrozole I-type crystal and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102070541A true CN102070541A (en) | 2011-05-25 |
| CN102070541B CN102070541B (en) | 2013-07-10 |
Family
ID=44029322
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010105210690A Active CN102070541B (en) | 2010-10-25 | 2010-10-25 | Letrozole I-type crystal and preparation method thereof |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN102070541B (en) |
| WO (1) | WO2012055163A1 (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012055163A1 (en) * | 2010-10-25 | 2012-05-03 | 深圳海王药业有限公司 | Letrozole type i crystal and preparation method thereof |
| CN103450099A (en) * | 2013-09-06 | 2013-12-18 | 杭州华东医药集团生物工程研究所有限公司 | Anastrozole, novel crystal form of monohydrate of anastrozole as well as preparation methods and application of novel crystal form |
| CN109721557A (en) * | 2017-10-27 | 2019-05-07 | 中国医学科学院药物研究所 | Letrozole crystalline substance II type solid matter and preparation method and its pharmaceutical composition and purposes |
| CN109721558A (en) * | 2017-10-27 | 2019-05-07 | 中国医学科学院药物研究所 | Letrozole crystalline substance type III solid matter and preparation method and its pharmaceutical composition and purposes |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007128561A1 (en) * | 2006-05-04 | 2007-11-15 | Synthon B.V. | Crystalline forms of letrozole and processes for making them |
| WO2007144896A1 (en) * | 2006-06-13 | 2007-12-21 | Natco Pharma Limited | A method of manufacture of letrozole |
| WO2008090565A1 (en) * | 2007-01-22 | 2008-07-31 | Natco Pharma Limited | Novel thermodynamically stable polymorphic form-l of letrozole |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102070541B (en) * | 2010-10-25 | 2013-07-10 | 深圳海王药业有限公司 | Letrozole I-type crystal and preparation method thereof |
-
2010
- 2010-10-25 CN CN2010105210690A patent/CN102070541B/en active Active
-
2011
- 2011-10-24 WO PCT/CN2011/001760 patent/WO2012055163A1/en active Application Filing
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007128561A1 (en) * | 2006-05-04 | 2007-11-15 | Synthon B.V. | Crystalline forms of letrozole and processes for making them |
| WO2007144896A1 (en) * | 2006-06-13 | 2007-12-21 | Natco Pharma Limited | A method of manufacture of letrozole |
| WO2008090565A1 (en) * | 2007-01-22 | 2008-07-31 | Natco Pharma Limited | Novel thermodynamically stable polymorphic form-l of letrozole |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012055163A1 (en) * | 2010-10-25 | 2012-05-03 | 深圳海王药业有限公司 | Letrozole type i crystal and preparation method thereof |
| CN103450099A (en) * | 2013-09-06 | 2013-12-18 | 杭州华东医药集团生物工程研究所有限公司 | Anastrozole, novel crystal form of monohydrate of anastrozole as well as preparation methods and application of novel crystal form |
| CN103450099B (en) * | 2013-09-06 | 2015-03-25 | 杭州华东医药集团新药研究院有限公司 | Anastrozole, novel crystal form of monohydrate of anastrozole as well as preparation methods and application of novel crystal form |
| CN109721557A (en) * | 2017-10-27 | 2019-05-07 | 中国医学科学院药物研究所 | Letrozole crystalline substance II type solid matter and preparation method and its pharmaceutical composition and purposes |
| CN109721558A (en) * | 2017-10-27 | 2019-05-07 | 中国医学科学院药物研究所 | Letrozole crystalline substance type III solid matter and preparation method and its pharmaceutical composition and purposes |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102070541B (en) | 2013-07-10 |
| WO2012055163A1 (en) | 2012-05-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1066727C (en) | Salts of an anti-migraine indole derivative | |
| CN102336801B (en) | Abiraterone acetate polymorphic substance and pharmaceutical composition | |
| CN102070541B (en) | Letrozole I-type crystal and preparation method thereof | |
| CN112142679B (en) | Gefitinib and vanilloid eutectic methanol solvate and preparation method thereof | |
| CN102321142A (en) | Abiraterone acetate crystal form and preparation method thereof | |
| CN103833626A (en) | Crystal form of chidamide and preparation method and application thereof | |
| CN110483486A (en) | A kind of western Tenylidone of Austria coughs up hydrochlorate crystal form and preparation method thereof | |
| EP2927226A1 (en) | Monohydrate crystal of fimasartan potassium salt, method for preparing same, and pharmacological composition comprising same | |
| CN101691372B (en) | Aildenafil citrate crystal form C and preparation method and application thereof | |
| CN101671337B (en) | Citric acid aildenafil crystal form A and preparation method and usage thereof | |
| CN101830903B (en) | Aildenafil citrate crystal form O, preparation method and application thereof | |
| CN100432090C (en) | I crystal form 3, 4', 5-trihydroxy-3-beta-D-heteroside | |
| CN108640910A (en) | Aprepitant L-PROLINE solvate-composition and eutectic | |
| CN107245054B (en) | Amorphous bulleyaconitine A compound and preparation method thereof | |
| CN101698668A (en) | Crystal form V of Aildenafil citrate and preparation method and application thereof | |
| CN100516080C (en) | 3,4', 5-trihydroxystilbene-3-beta-D-glucoside crystal form | |
| CN108014343A (en) | A kind of pharmaceutical composition for treating breast cancer and preparation method thereof | |
| CN102503935B (en) | Azelnidipine crystal form, preparation method for same and officinal composition thereof | |
| CN103073543A (en) | Preparation method and application of tropisetron citrate crystal form I | |
| CN101613385B (en) | Crystal form of 3,4',5-trihydroxy stilbene-3-beta-D-glucoside | |
| CN103524424A (en) | Crystal form VI of ambrisentan as well as preparation method and application thereof | |
| CN101991859A (en) | Beta-cyclodextrin inclusion compound of huperzine A, and preparation method and preparation thereof | |
| CN102558051A (en) | Tolvaptan crystal and medicine composition thereof | |
| CN101333189A (en) | Aripiprazole crystal form suitable for pharmaceutical use, preparation method and pharmaceutical compositions | |
| CN102666528A (en) | Crystalline CDC7 inhibitor salts |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |